At the 2018 Annual Meeting, cryopreservation minimums were left unchanged, remaining at the levels set in 2011. These minimums remain:
Neuro: $80,000 (or $100,000 to receive a waiver of the $180/year Comprehensive Member Standby fee).
Whole Body: $200,000 (or $220,000 to receive a waiver of the $180/year CMS fee)
Membership dues also remain unchanged.
Here are the results of the elections at the Alcor Annual Meeting on September 15, 2018:
All directors were unanimously re-elected:
Ralph Merkle, Ph.D.
Mike O’Neal, Ph.D.
Michael Riskin, Ph.D., CPA
Michael Seidl, Ph.D., J.D.
Brian Wowk, Ph.D.
President: Max More was re-relected unanimously.
CFO/treasurer: Michael Perry was re-relected unanimously.
Secretary: Michael Perry was re-relected unanimously.
Dale Allsop, Alcor member A-3152, a non-confidential, neurocryopreservation member, was pronounced on August 24, 2018 in Scottsdale, Arizona. He became Alcor’s 161st patient the same day.
More details will be added to this case summary after review and validation.
Herbert Drazen, Alcor member A-2887, a non-confidential, whole body member, was pronounced on August 13, 2018 (after an unknown amount of time before being discovered) in Pomona, New York. He became Alcor’s 160th patient that day, and arrived at Alcor for cool down on August 15, 2018.
(All times are in Mountain Time in 24-hour format.) On Monday, August 13, 2018 at 09:03 a Telemed alert was received, informing Alcor that non-confidential Alcor member Herbert Drazen of Pomona, New York had been pronounced deceased. The member lived alone in a small upstate New York community about an hour north of Manhattan.
The patient had been found in his home by a relative who had received a call from the dialysis center that the patient was late for an appointment. The police and paramedics were present at the time and they immediately released the patient as he was not considered to be a coroner’s case.
With the assistance of Alcor’s local mortician, a New York mortician was contacted and sent to retrieve the patient and pack him in dry ice as quickly as possible. Since the New York Mortician estimated that the patient had died approximately 24 hours (and perhaps considerably longer) prior to being found, it was decided by the Alcor Deployment Committee that it would not be possible to perfuse this patient. Therefore, the decision was made to pack the patient in dry ice as quickly as possible and then have him air shipped back to Alcor to be placed into liquid nitrogen. The New York mortician was very cooperative and helpful.
The patient departed JFK Airport in New York on Wednesday, August 15, 2018, at 15:06 and arrived at Phoenix, Sky Harbor Airport at 20:55. The patient was placed into cooldown at Alcor on August 20, 2018.
Ron Putirka, Alcor member A-1334, a non-confidential, neurocryopreservation member, was pronounced on July 22, 2018 in Las Vegas Nevada. He became Alcor’s 159th patient the same day.
On July 18, 2018, a close friend of Alcor member, Ron Putirka, a 73-year old man, notified Alcor that the member had been admitted to the Intensive Care Unit (ICU) at a hospital in Las Vegas. This was due to difficulty breathing, unresponsiveness, and a diagnosis of stage IV prostate cancer with multi-system organ failure. Ron’s career as a singer started in Detroit, MI when he was a teenager. In his later years, while living part of the time in Nevada, he had sung in many nightclubs in Las Vegas.
The Alcor Deployment Committee sent Suspended Animation (SA) to the patient’s location with their mobile operating vehicle. The immediate deployment was requested as the member was declining rapidly. After a four-day standby, the member was pronounced legally deceased at 03:11 hrs. on July 22, 2018. Ron arrived at Alcor 7 hours and 15 minutes after pronouncement. Less than six hours later, the cool down process begun.
A-1377, a confidential whole body member, was pronounced on June 18, 2018 in Raleigh, North Carolina. He became Alcor’s 158th patient the same day (although arrived at Alcor on June 19).
On Saturday, June 16, 2018, a TeleMed alert was sent out at 13:31 hrs stating that confidential Alcor member A-1377 was close to death. A decision was made by the Alcor Deployment Committee to have Suspended Animation (SA) deploy for standby. A flight was booked to depart that night at 22:30 hrs which would arrive at the destination on the following morning
at 06:15 hrs.
This 49-year-old member had developed esophageal cancer several years earlier which had progressed to stage IV despite an esophagectomy, radiation therapy, and several courses of chemotherapy.
At the time of this case, the member had been in an Intensive Care Unit (ICU) with presumed aspiration pneumonia and sepsis and had deteriorated despite therapy to the point that he had required high-dose vasopressor support and mechanical ventilation.
Based on the member’s condition, the family elected to withdraw support as soon as SA was on site and ready. When the member was pronounced, SA performed the stabilization protocol and then transferred the patient to a local funeral home for the washout procedure. The perfusion was completed at 19:31 hrs and preparations for transport were begun.
The patient arrived at Sky Harbor Airport in Phoenix, AZ at 15:06 hrs on June 19, 2018, and SA met with Alcor staff at 16:13 hrs for the patient handoff for cryoprotectant perfusion at Alcor.
The 2018 Alcor Annual Meeting will be held on Saturday September 15, 2018, starting at 11:00 am (MST) at the Alcor facility (7895 East Acoma Drive in Scottsdale, AZ). The start time is may change. The elections of directors and officers will be conducted at this meeting and a wide range of topic will be discussed publicly both before and after a lunch break. Members and the public are encouraged to attend this meeting. The 2018 Strategic Meeting is also scheduled the same weekend, including Friday and Sunday sessions. Some sessions are closed but a summary of the topics discussed at the 2018 Strategic Meeting will be posted to our blog and newsletter.
Timothy Hubley, A-1395, a non-confidential neuropreservation member was pronounced on May 13, 2018 in Jacksonville, Florida. He became Alcor’s 157th patient on May 14.
Timothy (Tim) Hubley suffered a stroke in January of 2016. He was starting to regain his speech and balance. He and his wife had just moved to Jacksonville, FL to be closer to his wife’s family. They would be able to help care for Tim and his wife. On Sunday, May 13, 2018, Alcor received a emergency alert about Tim. Tim and his family had sat down to dinner when a piece of steak became lodged in Tim’s throat. Chest thrusts and CPR were performed immediately by family members. Tim was taken to a nearby hospital but was pronounced legally deceased.
Alcor began making arrangements immediately to fly to Jacksonville and perform field cryoprotective perfusion. The Medical Examiner contacted Alcor and stated that an autopsy was required due to the patient’s suspected cause of death and because he did not have a primary physician to sign the death certificate. Alcor worked with the Medical Examiner and we were able to avoid an autopsy. The Medical Examiner released Tim to a local funeral home with no additional issues.
Eric Vogt of ICE (International Cryomedicine Experts) and Alcor’s Medical Response Director, Josh Lado, arrived in Jacksonville on Monday morning. Field cryoprotective perfusion was started 17 hours after legal death was declared. Cryoprotective perfusion started at 08:50 (MT) and was completed at 13:15. A terminal concentration of M22 was reached and maintained to ensure equilibrium. There was no evidence of edema. Overall, the perfusion went well apart from a temporary stoppage of flow that was resolved by repositioning the pump and tubing. The patient was then secured in a neuro shipper and cooled with dry ice.
The team left Jacksonville on Tuesday morning. Upon arrival back at Alcor, the patient was placed into the cooldown dewar and the computer system was initiated. Once cooldown is completed, Alcor will perform CT scans to determine the degree of success of the perfusion.
More details will be provided in a forthcoming case report.
Join us for the Northern California meeting on July 22 at 3:00pm
Zheng & Tim will be hosting the event at their home, 381 N Fernwood Circle, Sunnyvale, CA
Please bring a dish to share for the potluck
If you have any questions please contact Mark Galeck – 650-772-1251
Alcor is pleased to announce the creation of the Alcor Endowment Trust Supporting Organization. The Alcor Endowment is a Type II supporting organization intended to support the Alcor Life Extension Foundation. It will provide that support by prudently investing funds above and beyond what makes sense to allocate for general operations and research, and by providing a stable payment stream to Alcor to assist in the running of the organization.
The Alcor Endowment serves several purposes. It provides a structure for strategically investing Alcor’s funds in a way that will put the organization in an ever stronger position as time passes. It guards over $5 million of assets to benefit Alcor, a figure that is expected to grow over time, in a separate organization, making it more secure from lawsuits. It ensures a smooth disbursement of funds to Alcor in a way that both protects against market fluctuations and against future boards/management spending down Alcor’s assets for short-term needs.
The Alcor Endowment makes annual distributions to Alcor which will average very nearly 2% over the long-term. To buffer Alcor from large market fluctuations, increases or decreases in the annual distributions to Alcor can generally vary by no more than 10% either up or down from the previous year’s distribution. The exact distribution algorithm is legally binding on the Endowment pursuant to the Endowment legal documents. Having a set distribution policy also checks against spending down of the endowment by future boards.
Unlike the Patient Care Trust, or its new successor, the Alcor Care Trust, the Endowment’s investment strategy is geared more towards maximizing long-term returns and less towards minimizing year-to-year fluctuations. This is because the Endowment is not focused on paying the patient care expenses.
The Alcor Endowment Board consists of five members. At least three of these members must also be on the Board of Directors of Alcor proper. The current composition of the Endowment is:
Ralph Merkle (Alcor Director)
Mike O’Neal (Alcor Director)
Andy Aymeloglu (Alcor Director)
Donations can be made to the Alcor Endowment directly as an alternative to donating to Alcor. Alcor may also choose to transfer funds into the Endowment at its discretion. As of May 12, 2018, the Endowment had $5,980,706.73 under management. The full text of the operating agreement detailing the distribution policy, board composition, and other details can be found here.